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Background
Adalimumab (ADA) has been shown to be safe and
effective in a study of juvenilei d i o p a t h i ca r t h r i t i s( J I A )
patients aged 4-17 years at a dose of 24 mg/m
2 every
other week.
1
Aim
To determine the long-term efficacy and safety of ADA
in a subgroup of BSA-dosed JIA patients aged 4-12
years.
Methods
Patients with polyarticular course JIA (N=171) were
enrolled in a phase 3, randomized-withdrawal, double-
blind (DB), stratified, parallel-group study, which con-
sisted of a 16-wk open-label (OL) lead-in, a 32-wk DB
phase, and an up to 5 year OL extension phase that
included BSA dosing prior to a switch to fixed dose
(FD). Patients on ADA (24 mg/m
2;m a xd o s e ,4 0m g )
were evaluated based on ACR pediatric response criteria
for improvement (ACR Pedi 30/50/70/90) and moni-
tored for adverse events (AEs).
Results
Subjects in the 4-12-year-old subgroup (n=41) were 73%
female and 98% white, with a mean age of 9 years. At
baseline, mean PhyGA was 58.1, mean PaGA was 47.9,
AJC was 18.6, and DI-CHAQ was 1.0. ACR Pedi 30/50/
70/90 responses at wk 106 (Table) were comparable to
completer patients (n=62) in the overall population who
reached ~240 wks in the OL extension FD phase (95%/
90%/82%/69%). Improvements in core disease activity/
severity variables were maintained throughout the study
(Table 1). The most common AEs were infections and
injection site reactions; there were no opportunistic
infections, malignancies, or deaths. One patient in the
4 - 1 2 - y e a r - o l ds u b g r o u pd i s c o n t i n u e dd u et oA E s( v i r a l
illness and hydrocephalus secondary to mechanical com-
plications of nervous system device).
Conclusions
ADA was efficacious and well tolerated in a BSA-dosed
JIA subpopulation aged 4-12 years. ACR Pedi 30/50/70/
90 responses were maintained through 106 weeks. Over-
all, efficacy was comparable to the entire study popula-
tion, in whom maintenance of response was observed
throughout the entire study with ADA for up to 6 years.
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Table 1 ACR indicates American College of
Rheumatology; AJC, active joint count; DI-CHAQ,
disability index of childhood health assessment
questionnaire; PaGA, parent global assessment of well-
being; PhyGA, physician’s global assessment of disease
activity
Time points ACR 30/50/70/90 PhyGA PaGA AJC DI-CHAQ
Week 16 100/88/63/39 12.7 12.2 5.1 0.4
Week 48 100/96/92/69 6.3 8.3 2.9 0.2
Week 106 100/96/96/71 5.9 5.0 1.2 0.1
% of Pts Aged 4-12 Years Achieving ACR Pedi and Mean Values in Disease
Activity/Severity Variables by ADA Exposure Throughout the Study
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